Blueprint Medicines ROI - Return on Investment 2014-2024 | BPMC

Blueprint Medicines return on investment for the quarter ending June 30, 2024 was -42.72.

  • Blueprint Medicines average return on investment for 2023 was -110.61, a 63.26% decline from 2022.
  • Blueprint Medicines average return on investment for 2022 was -301.09, a 9.92% decline from 2021.
  • Blueprint Medicines average return on investment for 2021 was -334.26, a 0% decline from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

Blueprint Medicines ROI - Return on Investment 2014-2024 | BPMC

  • Blueprint Medicines average return on investment for 2023 was -110.61, a 63.26% decline from 2022.
  • Blueprint Medicines average return on investment for 2022 was -301.09, a 9.92% decline from 2021.
  • Blueprint Medicines average return on investment for 2021 was -334.26, a 0% decline from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$117.5B
Regeneron Pharmaceuticals (REGN)$111.6B
Bristol Myers Squibb (BMY)$109.4B
Gilead Sciences (GILD)$105.3B
CSL (CSLLY)$95.7B
GSK (GSK)$80.5B
Alnylam Pharmaceuticals (ALNY)$34.4B
Argenex SE (ARGX)$31.7B
BioNTech SE (BNTX)$29.2B
Biogen (BIIB)$27B
BeiGene (BGNE)$23.9B
Moderna (MRNA)$23.1B
Illumina (ILMN)$22.5B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$13.2B
Incyte (INCY)$13B
Exact Sciences (EXAS)$12.6B
Vaxcyte (PCVX)$12.4B
Insmed (INSM)$12.4B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.5B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.9B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.3B
Revolution Medicines (RVMD)$7.9B
Intra-Cellular Therapies (ITCI)$7.7B
Repligen (RGEN)$7.7B